ROSEN, SKILLED INVESTOR COUNSEL, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OGN

Group 1 - A class action lawsuit has been filed on behalf of purchasers of Organon & Co. securities between October 31, 2024, and April 30, 2025 [1] - Investors who purchased Organon securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - The lawsuit alleges that Organon's management provided misleading statements regarding the company's priorities, particularly concerning capital allocation and a significant reduction in quarterly dividends [5] Group 2 - The lawsuit claims that Organon concealed the importance of its debt reduction strategy following the acquisition of Dermavant, which led to a 70% decrease in the regular quarterly dividend [5] - Investors are encouraged to join the class action by contacting the Rosen Law Firm for more information [3][6] - The Rosen Law Firm has a strong track record in securities class actions, having recovered hundreds of millions of dollars for investors and being recognized for its success in this area [4]